On Wednesday, Vascular Solutions, Inc. (NASDAQ:VASC)’s shares inclined 14.53% to $39.49.
Vascular Solutions, Inc. (VASC) stated financial results for the second quarter ended June 30, 2015.
Worldwide revenue raised 22% from the second quarter of 2014 to $37.6 million, which exceeded the company’s revenue guidance range of $35.5 million to $36.5 million and set a new quarterly revenue record. U.S. revenue raised 14% to $28.7 million, while international revenue raised 60% to $8.9 million.
Gross margin was 66.3% in the second quarter contrast to 66.5% in the second quarter of 2014. The modest decline in gross margin resulted from the substantial growth in international revenue through the company’s independent distributor network. Vascular Solutions anticipates gross margin for the full year to be between 66.8% and 67.3%, subject to variations in product and geographic mix.
Vascular Solutions, Inc., a medical device company, provides various solutions to interventional cardiologists, interventional radiologists, electro physiologists, and vein practices worldwide. The company’s catheter products comprise GuideLiner catheters for use in various interventions; Pronto extraction catheters for treating acute myocardial infarction; Micro-Introducers for performing arterial and venous catheterization procedures; Langston to measure intravascular pressure gradients for the diagnosis of aortic valve stenosis; and SmartNeedle, a doppler-guided needle device designed to provide auditory ultrasound-guided access to arteries and veins.
Nektar Therapeutics (NASDAQ:NKTR)’s shares gained 1.51% to $12.79.
Nektar Therapeutics (NKTR) stated that partner Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, recently declared the publication of the complete data from the Phase II/III pivotal study and Phase I trial of BAX 855 in Blood, the journal of the American Society of Hematology. BAX 855 is Baxalta’s investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], a leading treatment for hemophilia A with more than 11 years of real-world patient experience.
Following on initial presentations of the data in 2014, the publication provides a comprehensive overview of the clinical trial results of BAX 855, which will be marketed in the United States under the brand name ADYNOVATE [Antihemophilic Factor (Recombinant), Pegylated] upon approval. The trial assessed the treatment’s safety and efficacy profiles for bleed prevention with a twice-weekly dosing plan, showing a mean half-life extension of 1.4- to 1.5-fold contrast with ADVATE. The positive study results were originally stated in August of 2014 and supported the company’s December 2014 submission for approval of BAX 855 to the United States Food and Drug Administration (FDA).
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
At the end of Wednesday’s trade, Cal-Maine Foods Inc (NASDAQ:CALM)‘s shares surged 0.47% to $53.76.
Cal-Maine Foods, Inc. (CALM) stated results for the fourth quarter and fiscal year ended May 30, 2015.
Net sales for the fourth quarter of fiscal 2015 were $403.0 million, contrast with net sales of $371.6 million for the fourth quarter of fiscal 2014. The Company stated net income of $46.1 million, or $0.96 per basic share and $0.95 per diluted share, for the fourth quarter of fiscal 2015, contrast with $31.5 million, or $0.66 per basic share and $0.65 per diluted share, for the fourth quarter of fiscal 2014.
For the fiscal year 2015, net sales were $1,576.1 million, contrast with net sales of $1,440.9 million for the preceding-year period. The Company stated net income of $161.3 million, or $3.35 per basic share and $3.33 per diluted share, for fiscal 2015, contrast with net income of $109.2 million, or $2.27 per basic share and $2.26 per diluted share, for the same period in fiscal 2014.
The net income per share numbers for the fourth quarter and year to date periods for fiscal 2015 and fiscal 2014 reflect the two-for-one stock split for shares of the Company’s common stock and Class A common stock, effective October 31, 2014.
Cal-Maine Foods, Inc. produces, grades, packages, markets, and distributes shell eggs. It produces and markets specialty shell eggs, counting nutritionally improved, cage free, organic, and brown eggs under the Egg-Land’s Best, Land O Lake, Farmhouse, and 4-Grain brand names; and private label specialty shell eggs.
Biomed Realty Trust Inc (NYSE:BMR), ended its Wednesday’s trading session with 0.98% gain, and closed at $20.52.
BioMed Realty Trust, Inc. (BMR) declared it will report results for its second quarter ended June 30, 2015 after the market closes on Tuesday, July 28, 2015.
Alan D. Gold, Chairman, President and Chief Executive Officer, and other members of the BioMed Realty administration team will host an investor conference call at 10:00 a.m. Pacific Time on Wednesday, July 29, 2015 to talk about the company’s financial results and operations for the quarter.
BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT) that focuses on providing real estate to the life science industry in the United States. Its tenants primarily comprise biotechnology and pharmaceutical companies, scientific research institutions, government agencies, and other entities involved in the life science industry. The company owns or has interests in 72 properties, representing 119 buildings with about 11.0 million rentable square feet.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
